Skip to content
Menu

Cryo-Cell International, Inc. CCEL

Full chart Compare
Set alert

Price alert · CCEL

All alert types
4.15 USD -0.05 (-1.19%)

Regular-session close

4.15 0.00 0.00%

After hours · Nov 20, 7:30 PM ET

4.08 Day range 4.40
2.89 52-week range 5.40
YTD
+20.64%
1 year
+3.23%

 

No chart data for this range yet.
Market cap
33.46M
Revenue (ttm)
31.84M
Profit margin
-28.04%
EPS (ttm)
-0.24
Shares out
8.06M
Forward P/E
96.63
Dividend
1.00 (12.77%)
Ex-dividend date
Nov 15, 2024
YTD return
+20.64%
1-year return
+3.23%
Volume
2.64K
Avg volume
13.78K
Open
4.15
Previous close
4.20
Day's range
4.08 – 4.40
52-week range
2.89 – 5.40
Beta
0.51
Price target
9.00 (+116.9%)
50-day average
7.71
200-day average
7.47

Key statistics

Enterprise value
72.73M
Price / sales
1.96
Revenue growth
2.50%
Free cash flow
-4.78M
Total cash
2.13M
Total debt
11.73M
Short % of float
0.38%

Fundamental scorecard

3 of 25 checks passed on CCEL’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 2 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Aug 31, 2026.

Financials — quick view

All financials
CCEL Revenue — quarterly 7.82M
CCEL Net income — quarterly 1.27M
CCEL EPS — quarterly 0.16

Earnings

CCEL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Oct 15, 2024Aug 1, 20240.000.13——
Jul 15, 2024May 1, 20240.000.08——
Apr 15, 2024Feb 1, 20240.000.07——
Feb 28, 2024Nov 1, 20230.000.26——
Oct 12, 2023Aug 1, 20230.000.08——
Jul 14, 2023May 1, 20230.000.03——

Upgrades / downgrades

CCEL analyst upgrades and downgrades
DateFirmActionFromTo
Aug 29, 2022Maxim Groupinit—Buy

About Cryo-Cell International, Inc.

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Sector
Healthcare
Industry
Medical Care Facilities
Country
United States

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on CCEL — it syncs with the Stock Master app.

Insider holders

CCEL insider holders
InsiderRelationLatest transactionDateShares held
MIKULINSKY OLEGChief Technology OfficerConversion of Exercise of derivative securityNov 11, 2024188,698

Institution ownership

CCEL institution ownership
Holder% heldSharesValueReported
Hamilton Lane Advisors Llc3.62%409,7343.17MSep 29, 2024
SFI Advisors, LLC1.46%165,3001.28MSep 29, 2024
Vanguard Group Inc1.03%116,848903.24KSep 29, 2024
MassMutual Trust Company FSB/ADV0.98%111,035858.30KSep 29, 2024
Geode Capital Management, LLC0.35%39,860308.12KSep 29, 2024
Northern Trust Corporation0.19%21,836168.79KSep 29, 2024

Fund ownership

CCEL fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund0.85%95,611739.07KSep 29, 2024
Fidelity Extended Market Index Fund0.20%22,852176.65KOct 30, 2024
Vanguard Extended Market Index Fund0.19%21,237164.16KSep 29, 2024
iShares Micro Cap ETF0.11%12,41595.97KOct 30, 2024
Fidelity Total Market Index Fund0.08%8,88468.67KOct 30, 2024
Fidelity Series Total Market Index Fund0.05%5,40841.80KOct 30, 2024